Chiral analysis of carvedilol and its metabolites hydroxyphenyl carvedilol and O-desmethyl carvedilol in human plasma by liquid chromatography-tandem mass spectrometry: Application to a clinical pharmacokinetic study

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 1015-1016, Issue , 2016, Pages 173-180

  Nardotto, Glauco Henrique Balthazar ^a   Coelho, Eduardo Barbosa ^a   Marques, Maria Paula ^a   Lanchote, Vera Lucia ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Carvedilol; Diabetes; Enantiomers; Metabolism; Pharmacokinetics; Plasma

Indexed keywords

CHROMATOGRAPHY; DRUG PRODUCTS; ENANTIOMERS; MASS SPECTROMETRY; MEDICAL PROBLEMS; METABOLISM; PATIENT TREATMENT; PHARMACOKINETICS; PHYSIOLOGY; PLASMAS;

ADRENERGIC ANTAGONIST; ANTIHYPERTENSIVE DRUGS; CARVEDILOL; CLINICAL PHARMACOKINETICS; LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY; OXIDATIVE METABOLISM; SEQUENTIAL ANALYSIS; TYPE 2 DIABETES MELLITUS;

LIQUID CHROMATOGRAPHY;

CARVEDILOL; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; DRUG METABOLITE; HYDROXYPHENYL CARVEDILOL; O DESMETHYL CARVEDILOL; UNCLASSIFIED DRUG; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAZOLE DERIVATIVE; PROPANOLAMINE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CASE REPORT; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG METABOLISM; ENANTIOMER; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACOKINETICS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SEQUENTIAL ANALYSIS; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; BLOOD; CHEMISTRY; METABOLISM; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL; STEREOISOMERISM;

ADRENERGIC BETA-ANTAGONISTS; CARBAZOLES; CHROMATOGRAPHY, LIQUID; DIABETES MELLITUS, TYPE 2; HUMANS; LINEAR MODELS; MIDDLE AGED; PROPANOLAMINES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; STEREOISOMERISM; TANDEM MASS SPECTROMETRY;

EID: 84959127143     PISSN: 15700232     EISSN: 1873376X     Source Type: Journal    
DOI: 10.1016/j.jchromb.2016.02.028     Document Type: Article

References (21)

1. Packer M., Bristow M.R., Cohn J.N., Colucci W.S., Fowler M.B., Gilbert E.M., Shusterman N.H. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N. Engl. J. Med. 1996, 334:1349-1355.
2. Honda M., Nozawa T., Igarashi N., Inoue H., Arakawa R., Ogura Y., Okabe H., Taguchi M., Hashimoto Y. Effect of CYP2D6*10 on the pharmacokinetics of R- and S-carvedilol in healthy Japanese volunteers. Biol. Pharm. Bull. 2005, 28:1476-1479.
3. Ruffolo R.R., Gellai M., Hieble J.P., Willette R.N., Nichols A.J. The pharmacology of carvedilol. Eur. J. Clin. Pharmacol. 1990, 38:S82-S88.
4. Neugebauer G., Akpan W., Kaufmann B., Reiff K. Stereoselective disposition of carvedilol in man after intravenous and oral administration of the racemic compound. Eur. J. Clin. Pharmacol. 1990, 38:S108-S111.
5. Tenero D., Boike S., Boyle D., Ilson B., Fesniak H.F., Brozena S., Jorkasky D. Steady-state pharmacokinetics of carvedilol and its enantiomers in patients with congestive heart failure. J. Clin. Pharmacol. 2000, 40:844-853.
6. Neugebauer G., Neubert P. Metabolism of carvedilol in man. Eur. J. Drug Metab. Pharmacokinet. 1991, 16:257-260.
7. Neugebauer G., Akpan W., Vanmöllendorff E., Reiff K. Pharmacokinetics and disposition of carvedilol in humans. J. Cardiovasc. Pharmacol. 1987, 10:S85-S88.
8. Oldham H.G., Clarke S.E. In vitro identification of the human cytochrome P450 enzymes involved in the metabolism of R(+)- and S(-)-carvedilol. Drug Metab. Dispos. 1997, 25:970-977.
9. Gehr T.W.B., Tenero D.M., Boyle D.A., Qian Y., Sica D.A., Shusterman N.H. The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency. Eur. J. Clin. Pharmacol. 1999, 55:269-277.
10. Takekuma Y., Yagisawa K., Sugawara M. Mutual inhibition between carvedilol enantiomers during racemate glucuronidation mediated by human liver and intestinal microsomes. Biol. Pharm. Bull. 2012, 35:151-163.
11. Li J.W., Wang L., Wang S.H., Chen M.C., Gu E.M., Hu G.X., Ge R.S. Simultaneous quantification of carvedilol and its metabolites in rat plasma by ultra performance liquid chromatography tandem mass spectrometry and pharmacokinetic application. J. Chromatogr. B 2015, 974:138-146.
12. Eisenberg E.J., Patterson W.R., Kahn G.C. High-performance liquid-chromatographic method for the simultaneous determination of the enantiomers of carvedilol and its ortho-desmethyl metabolite in human-plasma after chiral derivatization. J. Chromatogr. 1989, 493:105-115.
13. Furlong M.T., He B., Mylott W., Zhao S., Mariannino T., Shen J., Stouffer B. A validated enantioselective LC-MS/MS assay for the simultaneous determination of carvedilol and its pharmacologically active 4'-hydroxyphenyl metabolite in human plasma: application to a clinical pharmacokinetic study. J. Pharm. Biomed. Anal. 2012, 70:574-579.
14. Bioanalytical Method Validation Guidance for Industry U.S. food and drug administration (FDA). Center for Drug Evaluation and Research (CDER) 2001, 25. Center for Veterinary Medicine (CVM), Rockville, MD, USA.
15. Guideline on bioanalytical method validation European Medicines Agency (EMEA) 2011, 23. Commitee for Medicinal Products for Human Use (CHMP), London.
16. Magiera S., Adolf W., Baranowska I. Simultaneous chiral separation and determination of carvedilol and 5'-hydroxyphenyl carvedilol enantiomers from human urine by high performance liquid chromatography coupled with fluorescent detection. Cent. Eur. J. Chem. 2013, 11:2076-2087.
17. Snyder L.R., Kirkland J.J., Glajch J.L. Practical HPLC Method Development 1997, Wiley, New York. Second ed.
18. Poole C.F. The Essence of Chromatography 2003, Elsevier Science Amsterdam, The Netherlands. First ed.
19. Tenero D.M., Henderson L.S., Baidoo C.A., Harter A.H., Campanile A.M., Danoff T.M., Boyle D. Pharmacokinetic properties of a new controlled-release formulation of carvedilol. Am. J. Cardiol. 2006, 98:5L-16L.
20. Saito M., Kawana J., Ohno T., Hanada K., Kaneko M., Mihara K., Shiomi M., Nagayama M., Sumiyoshi T., Ogata H. Population pharmacokinetics of R- and S-Carvedilol in japanese patients with chronic heart failure. Biol. Pharm. Bull. 2010, 33:1378-1384.
21. n experiments. Biomed. Chromatogr. 2012, 26:720-736.